Last reviewed · How we verify
disulfiram plus lorazepam
Disulfiram inhibits aldehyde dehydrogenase to create an aversive reaction to alcohol, while lorazepam is a benzodiazepine that enhances GABAergic inhibition to reduce anxiety and withdrawal symptoms.
Disulfiram inhibits aldehyde dehydrogenase to create an aversive reaction to alcohol, while lorazepam is a benzodiazepine that enhances GABAergic inhibition to reduce anxiety and withdrawal symptoms. Used for Alcohol use disorder with concurrent anxiety or withdrawal symptoms.
At a glance
| Generic name | disulfiram plus lorazepam |
|---|---|
| Sponsor | University of New Mexico |
| Drug class | Aldehyde dehydrogenase inhibitor plus benzodiazepine |
| Target | Aldehyde dehydrogenase (ALDH); GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Disulfiram blocks the enzyme aldehyde dehydrogenase, causing acetaldehyde accumulation if alcohol is consumed, producing an unpleasant disulfiram-alcohol reaction that discourages drinking. Lorazepam potentiates GABA neurotransmission at the CNS, reducing anxiety, tremor, and other withdrawal symptoms associated with alcohol cessation. This combination addresses both the behavioral deterrent and symptomatic management aspects of alcohol use disorder treatment.
Approved indications
- Alcohol use disorder with concurrent anxiety or withdrawal symptoms
Common side effects
- Disulfiram-alcohol reaction (flushing, nausea, chest pain, hypotension)
- Sedation
- Dizziness
- Peripheral neuropathy (disulfiram)
- Hepatotoxicity (disulfiram)
- Dependence risk (lorazepam)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |